SCHEMBL7090904

SCHEMBL7090904

CSc1ccc(C(=O)C(=O)c2cccc(C)c2)cc1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.50
CES2 O00748 4/20 0.48
CES1 P23141 4/20 0.48
HDAC8 Q9BY41 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.45
PLK1 P53350 1/20 0.44
KCNK3 O14649 1/20 0.44
KCNH2 Q12809 1/20 0.44
KCNK9 Q9NPC2 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
HPGD P15428 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
KDM4E B2RXH2 2/20 0.43
MAPT P10636 2/20 0.43
POLB P06746 2/20 0.43
CTDSP1 Q9GZU7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7810525 0.86 CNR2 (0.51) PARP1HDAC8HDAC6SMN1; SMN2PLK1
SCHEMBL3753879 0.83 PARP1 (0.68) PARP1CES2CES1HDAC8HDAC6
SCHEMBL3753584 0.81 CES2 (0.65) PARP1CES2CES1HDAC8HDAC6
SCHEMBL31529061 0.81 CES2 (0.65) PARP1CES2CES1HDAC8HDAC6
SCHEMBL7090547 0.81 CES2 (0.65) CES2CES1PLK1HPGDMAPT
SCHEMBL7089334 0.81 CES2 (0.70) CES2CES1HDAC6SMN1; SMN2PLK1
SCHEMBL5859663 0.81 PLK1 (0.61) CES2CES1SMN1; SMN2PLK1MEN1
SCHEMBL7090589 0.79 CES2 (0.65) CES2CES1SMN1; SMN2PLK1MEN1
SCHEMBL7088060 0.78 GSK3B (0.49) CES2CES1SMN1; SMN2PLK1MEN1
SCHEMBL7087796 0.76 CES2 (0.45) PARP1CES2CES1HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030050330-A1 4,5-subtstituted imdazolyl compounds for the treatment of inflammation G.D. SEARLE & CO. 2003-03-13 US disclosed
EP-0772601-B1 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION SEARLE & CO (US) 2002-09-18 EP disclosed
US-6426360-B1 ANTIARTHRITIC AGENTS G D SEARLE & CO. 2002-07-30 US disclosed
EP-1211244-A2 4,5-substitued imidazolyl compounds for the treatment of inflammation G.D. Searle & Co. (US) 2002-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030050330-A1 4,5-subtstituted imdazolyl compounds for the treatment of inflammation AHR, HACL2, IRAK2 PARP1 2708/4885CES2 984/4885CES1 374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.